Exploring the economics of gene therapy innovation and price
Amanda Whittal, Esther Idicula, Adam Hutchings
Gene therapies are revolutionising the treatment of severe conditions, offering previously unattainable advances in health gains. Simultaneously, this therapeutic potential is matched by concerns around price and affordability. Are these fears reflective of reality? To address this question requires an understanding of the political and economic environment within which gene therapies exist, and how companies make decisions and investments within these constraints. This paper seeks to determine how to make this life-changing innovation sustainable for both society and manufacturers.